GlobalRPH - Gout News

Medical News

< back to feeds
Gout News
Low-Dose Colchicine (Colcrys) Is Rapid, Effective Treatment For Acute Gout Flares PHILADELPHIA - New data show that low-dose colchicine (ColcrysTM) rapidly controls acute gout flares. The results, which were presented at the 2009 Annual Scientific Meeting of the American College of Rheumatology, are drawn from a secondary analysis of the phase III Acute Gout Flare Receiving Colchicine Evaluation (AGREE) trial. ...more	26 Oct 2009
Ardea Biosciences Announces Additional Positive Results From A Phase 2a Study Of RDEA594 At The 2009 ACR/ARHP Annual Scientific Meeting Ardea Biosciences, Inc. (Nasdaq: RDEA) announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. ...more	21 Oct 2009
For Management Of Hyperuricemia In Patients With Gout, Uloric (Febuxostat) Demonstrated Efficacy Additional analysis showed that reduction and long-term maintenance of normal serum urate levels also reduced risk of future gout flares Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to ...more	21 Oct 2009
New Data Presented At ACR Meeting Demonstrates Colcrys(TM) (Colchicine, USP) Significantly Reduces Pain Of Acute Gout Flare Within 24 Hours URL Pharma, Inc., announced data from a pivotal Phase III study demonstrating that Colcrys(TM) (colchicine, USP), a low-dose colchicine, reduced the pain of gout flares within a 24-hour period as effectively as high-dose colchicine with a side effect profile statistically indistinguishable from placebo. These data and two other Colcrys studies were presented this week at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting in Philadelphia. ...more	20 Oct 2009
FDA Approves Colcrys(TM) (colchicine, USP) For Prevention Of Gout Flares URL Pharma, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Colcrys(TM) (colchicine, USP) for the prophylaxis (prevention) of gout flares. Colcrys was first approved by the FDA on July 30, 2009 for the treatment of acute gout flares when taken at the first sign of a flare. Colcrys is an oral, branded form of colchicine that has been formulated for optimal efficacy and tolerability. ...more	20 Oct 2009
ULORIC(R) (febuxostat) Demonstrated Efficacy For Management Of Hyperuricemia In Patients With Gout Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to ...more	19 Oct 2009
Rochester-Led Parkinson's Study Pays Off Again, 2 Decades Later Parkinson disease progresses more slowly in patients who have higher levels of urate, a chemical that at very high level is associated with gout, scientists have found. While it's unknown whether the high levels actually somehow protect patients or simply serve as a marker of protection, the finding supports the idea that patients and doctors may one day be able to better predict the course of the illness. ...more	13 Oct 2009
BioCryst Announces Initiation Of Phase 2 Study Of BCX4208 For The Treatment Of Gout BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it is initiating a Phase 2 study of BCX4208 for the treatment of gout. The primary objective of BioCryst's Phase 2 study is to determine the effect of different doses of orally administered BCX4208 on serum uric acid levels in patients with gout. The gout trial is expected to enroll up to 120 subjects. "Over the last few decades gout has markedly increased in incidence and prevalence, both in the U.S. and elsewhere. ...more	29 Sept 2009
EnzymeRx Announces Its IND For Uricase-PEG 20 Becomes Effective EnzymeRx, LLC a clinical-stage biotechnology company, announced that its Investigational New Drug (IND) application for Uricase-PEG 20, filed with the U.S. Food and Drug Administration (FDA) last month, has become effective. EnzymeRx filed this IND for intravenous Uricase-PEG 20 in the management of elevated uric acid levels associated with tumor lysis syndrome. ...more	28 Sept 2009
Savient Pharmaceuticals Receives Complete Response Letter From U.S. Food And Drug Administration For KRYSTEXXA(TM) Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) stating that the FDA can not at this time approve the Company's Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. ...more	04 Aug 2009
FDA Approves Colchicine For Acute Gout, Mediterranean Fever The U.S. Food and Drug Administration has approved Colcrys to treat acute flairs in patients with gout, a recurrent and painful form of arthritis, and patients with familial Mediterranean fever (FMF), an inherited inflammatory disorder. The medication's active ingredient is colchicine, a complex compound derived from the dried seeds of a plant known as the autumn crocus or meadow saffron (Colchicum autumnale). ...more	02 Aug 2009
Ardea Biosciences Initiates Phase 2b Clinical Trial Of RDEA594, Lead Product Candidate For The Treatment Of Gout Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced that it has initiated a Phase 2b clinical trial of RDEA594, its lead product candidate in development for the management of hyperuricemia and gout. The Company also announced the selection of RDEA684, a next-generation URAT1 inhibitor, as a development candidate for the same indication. ...more	22 July 2009
Johns Hopkins Scientists Out A Gene For Gout Having partnered last year with an international team that surveyed the genomes of 12,000 individuals to find a genetic cause for gout, Johns Hopkins scientists now have shown that the malfunctioning gene they helped uncover can lead to high concentrations of blood urate that forms crystals in joint tissue, causing inflammation and pain - the hallmark of this disease. ...more	20 June 2009
Scientists Out A Gene For Gout Having partnered last year with an international team that surveyed the genomes of 12,000 individuals to find a genetic cause for gout, Johns Hopkins scientists now have shown that the malfunctioning gene they helped uncover can lead to high concentrations of blood urate that forms crystals in joint tissue, causing inflammation and pain the hallmark of this disease. ...more	20 June 2009
FDA Appointed Arthritis Advisory Committee Recommends U.S. Food And Drug Administration Approval For KRYSTEXXA(TM) For Refractory Chronic Gout Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a vote of 14 to 1 that KRYSTEXXA(TM) (pegloticase), a biologic PEGylated uricase enzyme, be granted marketing approval by the FDA for the treatment of refractory chronic gout. ...more	17 June 2009
Ardea Biosciences Announces Positive Interim Phase 2a Results For Lead Gout Drug, RDEA594 Ardea Biosciences, Inc. (Nasdaq:RDEA) announced positive interim results from an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as additional positive results from completed Phase 1 studies of RDEA594 in normal, healthy volunteers. ...more	14 June 2009
Role For Innate, Not Adaptive, Immunity Revealed By Autoinflammatory Disease Model Researchers at the University of California, San Diego School of Medicine have developed the first mouse model for auto-inflammatory diseases, disorders that involve the over-activation of the body's innate, primitive immune system. Their study, published early on-line in Cell Immunity on June 4, suggests that the innate - not adaptive - immune system drives auto-inflammatory diseases. ...more	06 June 2009
What Is Bursitis? What Causes Bursitis? Bursitis happens when the bursa is inflamed. The burse acts as a cushion between bones, tendons, joints and muscles - bursae are fluid-filled sacs (the plural of bursa is bursae). People with bursitis will feel pain at the site of inflammation. The medical word "bursa" comes from the Latin bursa, meaning a purse, which is what a bursa resembles. According to Medilexicon's ...more	02 June 2009
New Diagnostic Method For Gout: Dual Energy Computed Tomography Instead Of Joint Aspiration The most reliable method of diagnosing gout is to aspirate the joint in order to obtain fluid to verify the presence of monosodium urate crystals (uric acid). Up to now, computed tomography (CT) has played a limited role in the evaluation of gout, since conventional CT systems cannot reliably verify deposits of uric acid. ...more	29 May 2009
The Gout & Uric Acid Education Society (GUAES) Announces New Survey Results Highlighting Major Gaps In Public Awareness Of Gout The Gout & Uric Acid Education Society announced that new survey results reveal alarming gaps in the public's awareness of gout, a painful and potentially debilitating form of arthritis that affects three to five million Americans. In a survey of more than 2,000 Americans, 65% of adults admitted to being "not at all knowledgeable" about gout and just over 70% did not know that gout is a form of arthritis. In fact, gout is the most common form of inflammatory arthritis among adults. ...more	23 May 2009
Pages of Results: 1 2 3 [Next] [Last Page]
Gout News courtesy of Medical News Today	back to top

Medical News

Looking for a Job?

Career Center

Popular Tools

Disclaimer Contact Us Privacy Policy Website Search	We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc.